Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF

Aims Iron deficiency is common in patients with heart failure (HF). In AFFIRM‐AHF, ferric carboxymaltose (FCM) reduced the risk of hospitalisations for HF (HHF) and improved quality of life vs. placebo in iron‐deficient patients with a recent episode of acute HF. The objective of this study was to e...

Full description

Saved in:
Bibliographic Details
Published in:European journal of heart failure 2021-10, Vol.23 (10), p.1687-1697
Main Authors: McEwan, Phil, Ponikowski, Piotr, Davis, Jason A., Rosano, Giuseppe, Coats, Andrew J.S., Dorigotti, Fabio, O'Sullivan, Donal, Ramirez de Arellano, Antonio, Jankowska, Ewa A.
Format: Article
Language:English
Subjects:
Cost-Benefit Analysis
Cost‐effectiveness
Ferric carboxymaltose
Ferric Compounds - therapeutic use
Focused Issue on Comorbidities
Heart failure
Heart Failure - complications
Heart Failure - drug therapy
Humans
Iron Deficiencies
Iron deficiency
Maltose - analogs & derivatives
Quality of Life
Stroke Volume
Ventricular Function, Left
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Iron deficiency is common in patients with heart failure (HF). In AFFIRM‐AHF, ferric carboxymaltose (FCM) reduced the risk of hospitalisations for HF (HHF) and improved quality of life vs. placebo in iron‐deficient patients with a recent episode of acute HF. The objective of this study was to estimate the cost‐effectiveness of FCM compared with placebo in iron‐deficient patients with left ventricular ejection fraction
ISSN:1388-9842
1879-0844
DOI:10.1002/ejhf.2270